Alvarez & Marsal Appoints Four New Managing Directors in Its Paris Office
Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of four Paris-based Managing Directors, Jonathan Gibbons, Guillaume Martinez, Frederic Steiner and Donatien Chenu, to the firm’s Global Transaction Advisory Group. These appointments advance A&M’s strategic expansion plans to meet local market demand in France, enhance its cross-border M&A offering and help clients address increasingly complex regional, European and global regulatory requirements.
The addition of Messrs. Gibbons, Martinez, Steiner and Chenu, all formerly with one of the Big Four in France, completes the latest phase of A&M’s European strategic growth plan following the launch of the firm’s Stockholm office and Nordics expansion in 2017 that added to existing transaction advisory activities in the U.K., Germany, and Netherlands. They will bolster A&M’s suite of integrated global transaction advisory services that provide clients with a differentiated offering for due diligence and transaction advisory requirements.
A&M’s market share continues to expand with the firm’s European practices experiencing strong growth over the past two years leading to work on a range of flagship European private equity deals. With A&M’s operational focus and market leading capabilities in Private Equity and Corporate Performance Improvement, A&M is uniquely placed to provide a differentiated approach to due diligence and take on the challenges of current market conditions faced by clients.
Antonio "Tony" Alvarez III, Managing Director and A&M’s European Practice lead, said, “These appointments support our global expansion strategy along with our capability building plans in France and Europe. New audit regulation and rotation rules are impacting the provision of non-audit services and generating greater conflicts in providing those services to clients. As growing numbers of Big Four professionals across Europe look beyond the traditional firms, A&M’s platform is acknowledged to be less restrictive enabling greater access for practice growth.”
Paul Aversano, Managing Director and Global Practice Leader of A&M’s Global Transaction Advisory Group, said, “The growth of our transaction advisory presence in France supports the firm’s commitment to meet local market needs and global market M&A demands with our unique and differentiated approach. These appointments are the latest of several growth areas in France and Europe for A&M to enable us to continue our European expansion.”
Managing Director and European Practice Lead with A&M’s Transaction Advisory Group, David Evans, added, “Jonathan’s, Guillaume’s, Frederic’s, and Donatien’s in-depth knowledge advances our ability to help private equity firms and corporate clients maximize value on a pan-European basis. We expect the French team to grow rapidly as client needs continue to escalate.”
Tarek Hosni, the France country leader and Managing Director with A&M Paris, stated, “The addition of these senior transaction professionals will enable us to increase our scale and service for French private equity firms as well as France based multinationals. A leading protagonist of positive transformation in France, we now also intend to deliver in France our internationally recognized expertise in transaction advisory services. This marks the start of our future growth plans for A&M France.”
A&M’s new Transaction Advisory Managing Directors have extensive cross-border and global transaction experience working with private equity and multi-national corporations throughout Europe and the world. The team’s collective experience spans numerous sectors including TMT, manufacturing, retail and consumer goods and financial services. For more information on Messrs. Gibbons, Martinez, Steiner and Chenu, please click on the links to their bios below:
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) when conventional approaches are not enough to make change and achieve results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services.
With over 3000 people across four continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, help organizations transform operations, catapult growth and accelerate results through decisive action. Comprised of experienced operators, world-class consultants, former regulators and industry authorities, A&M leverages its restructuring heritage to turn change into a strategic business asset, manage risk and unlock value at every stage of growth.
Note to Editor:
About Alvarez & Marsal Global Transaction Advisory Group
A&M’s Global Transaction Advisory Group provides investors and lenders the answers needed to get the deal done. We combine our firm’s deep operational, industry and functional resources with Big Four-quality financial accounting and tax expertise to assess key deal drivers and focus on the root cause of any critical deal issues. As the largest transaction advisory practice outside the Big Four, our global integrated teams help private equity, sovereign wealth funds, family offices and hedge funds as well as corporate acquirers unlock value across the investment lifecycle.
The firm’s Global Transaction Advisory Group includes over 350 professionals in 22 offices throughout the U.S., Latin America, Europe, India and Asia. Our global team has extensive industry knowledge across multiple sectors including, but not limited to, dedicated industry verticals in healthcare, software & technology, energy and financial services.
Alvarez & Marsal
Helene Willberg, +46 70 589 9763
Sandra Sokoloff, +1 212-763-9853
Senior Director of Global Public Relations
Margaret Cameron-Waller, +44 (0)207 7155202
Director of Marketing U.K. & Europe
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu